Table 1.
Demographic Features of Included Patients
| Cohort (n = 91) | |
|---|---|
| Demographics | |
| Age, years, median (IQR) | 37 (27–50) |
| Male sex, n (%) | 45 (49.5%) |
| Disease duration, years, median (IQR) | 11.6 (7.5–15.8) |
| CD, n (%) | 59 (64.8) |
| UC, n (%) | 32 (35.2) |
| BMI, median (IQR) | 23.8 (20.2–29.2) |
| Obese, n (%) | 22 (24.2) |
| Past smoking, n (%) | 31 (40.3) |
| SMI, males, median (IQR) | 56.9 (46.2–63.3) |
| SMI, females, median (IQR) | 36.1 (34–43) |
| Major surgery, n (%) | 67 (73.6) |
| Laboratory values | |
| WBC, 109/L, median (IQR) | 10.6 (10–12.6) |
| Hemoglobin, g/dL, median (IQR) | 10.7 (10.2–12) |
| Platelet count, 109/L, median (IQR) | 258.5 (183.8–302.5) |
| Albumin, g/dL, median (IQR) | 3.4 (2.6–3.9) |
| CRP, mg/L, median (IQR) | 23 (6.5–85) |
| Protein, g/dL, median (IQR) | 6.5 (5.5–7.4) |
| BUN, mg/dL, median (IQR) | 9 (8–9) |
| Creatinine, mg/dL, median (IQR) | 0.9 (0.7–1) |
| Medication use | |
| Steroid use, n (%) | 30 (33) |
| Immunomodulator, n (%) | 12 (13.2) |
| Anti-TNF, n (%) | 21 (23.1) |
| Anti-integrin, n (%) | 10 (11) |
BUN, blood urea nitrogen; CRP, C-reactive protein; TNF, tumor necrosis factor; WBC, white blood cell.